Company intelligence / Profile preview
Acure Pharma
- Ownership
- Private
- Employees
- ~4
- Development stage
- Commercial
Overview
Acure Pharma AB has a proprietary small molecule platform focused on GPCRs, with at least one program (AMAP-102) reaching Phase 2 for musculoskeletal pain, and others in preclinical or discontinued stages.
- Therapeutic areas
- ImmunologyNeurologyCardiovascularEndocrinologyRheumatology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Acure Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acure Pharma.